NAII NATURAL ALTERNATIVES INTERNATIONAL INC
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 787253 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.1%
TTM net income YoY-92.6%
TTM EPS YoY-89.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin4.4%
Operating margin-16.3%
Net margin-17.2%
FCF margin-5.0%
EBITDA margin-12.8%
Returns
ROE-39.4%
ROA-16.9%
ROIC (approx.)-30.3%
Asset turnover0.98x
Leverage & solvency
Liabilities / assets58.8%
Debt / equity0.23x
Current ratio1.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $142.51M | $129.86M |
| Cost of revenue | $133.52M | $120.57M |
| Gross profit | $9.00M | $9.29M |
| R&D expense | $2.30M | $1.80M |
| Operating income | -$18.75M | -$8.66M |
| Pretax income | -$20.27M | -$10.74M |
| Income tax | $430,000 | $2.83M |
| Net income | -$20.70M | -$13.57M |
| EBITDA | -$14.04M | -$4.10M |
| EPS (basic) | -3.43 | -2.28 |
| EPS (diluted) | -3.43 | -2.28 |
| Weighted avg. shares (diluted) | 6.03M | 5.95M |
| Banking | ||
| Net interest income | -$1.19M | -$915,000 |
| Balance sheet | ||
| Cash & equivalents | $7.39M | $12.32M |
| Receivables | $20.65M | $14.64M |
| Inventory | $30.75M | $24.87M |
| Current assets | $65.43M | $59.28M |
| PP&E, net | $35.60M | $50.89M |
| Total assets | $126.45M | $151.94M |
| Current liabilities | $37.72M | $28.80M |
| Long-term debt | $10.90M | — |
| Total debt | $10.90M | — |
| Total liabilities | $76.49M | $83.51M |
| Shareholders' equity | $49.96M | $68.43M |
| Net debt | $3.51M | — |
| Shares outstanding | 6.27M | 6.18M |
| Cash flow statement | ||
| Operating cash flow | -$8.92M | $5.93M |
| Capital expenditure | $3.70M | $3.61M |
| Free cash flow | -$12.62M | $2.32M |
| Investing cash flow | -$3.70M | -$3.61M |
| Financing cash flow | $7.77M | -$1.97M |
| Depreciation & amortization | $4.71M | $4.56M |
| Stock-based compensation | $603,000 | $977,000 |
| Share buybacks | $89,000 | $178,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.